about
Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studiesTranslating pharmacogenomics: challenges on the road to the clinicWorldwide distribution of NAT2 diversity: implications for NAT2 evolutionary historyPharmacogenomics and drug response in cardiovascular disordersPolymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemiaPharmacogenomics in diabetes mellitus: insights into drug action and drug discoveryGenotyping panel for assessing response to cancer chemotherapy.GENE-LEVEL PHARMACOGENETIC ANALYSIS ON SURVIVAL OUTCOMES USING GENE-TRAIT SIMILARITY REGRESSION.Expectations, validity, and reality in pharmacogenetics.Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses.Globalization of pediatric research: analysis of clinical trials completed for pediatric exclusivity.Phenobarbital for the treatment of epilepsy in the 21st century: a critical review.Gene-environment interactions in human diseases.Applying genome-wide gene-based expression quantitative trait locus mapping to study population ancestry and pharmacogeneticsPharmacogenetics and the concept of individualized medicine.Genotypic approaches to therapy in children: a national active surveillance network (GATC) to study the pharmacogenomics of severe adverse drug reactions in children.CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.Improving the prediction of pharmacogenes using text-derived drug-gene relationships.Identifying the genotype behind the phenotype: a role model found in VKORC1 and its association with warfarin dosing.The genetics of human drug responseGenomic medicine: genetic variation and its impact on the future of health care.Pharmacogenetics in drug development.Industry-sponsored clinical research outside high-income countries: an empirical analysis of registered clinical trials from 2006 to 2013.Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia.A penalized likelihood approach for investigating gene-drug interactions in pharmacogenetic studiesMoving towards individualized medicine with pharmacogenomics.Pharmacogenetic approaches to rheumatoid arthritis.Pharmacogenomics: bench to bedside.Pharmacogenetics and drug development: the path to safer and more effective drugs.Genetically modified mouse models for pharmacogenomic research.Pharmacogenetics - five decades of therapeutic lessons from genetic diversity.Pharmacogenomics in early-phase clinical developmentPriorities and standards in pharmacogenetic research.Toward the 1,000 dollars human genome.Pharmacogenomics in depression and antidepressantsSNPselector: a web tool for selecting SNPs for genetic association studies.Pharmacogenomics and therapeutic prospects in Alzheimer's disease.Genetic variation in the cysteine biosynthesis pathway causes sensitivity to pharmacological compoundsPharmacogenetics/genomics and personalized medicine.
P2860
Q21091172-16FE8E8C-E9D5-4A44-9FFF-BDC57264D6D3Q21092371-B45AB652-5FE3-4022-894E-B33F04ADE350Q21283781-CFC8F56F-5987-4EDB-8935-CB013CC63AE4Q28171051-AA6FDC8F-5864-4E3D-A7C8-E2B4228508B9Q28245060-3C919B68-0233-4F31-8DF8-5302B5960380Q28274686-C8504D37-322A-4133-A60B-3676C28F88B1Q33343095-BB210422-9010-495C-957E-8F429DA386DEQ33881221-96696BB8-B012-4978-9D01-DD4D639D54B3Q33926313-7C2B5748-9CD6-483E-B8C5-5991F23131D8Q33936573-D055CF78-D412-4B92-811C-6392A21DAB50Q34041800-EFA0CC01-37B5-4B0E-9568-9CFC712A6EF0Q34101575-02F5676A-955C-4291-9353-CD8D088AE03CQ34343308-196B929A-2EF8-42B6-A993-DA676C1D15F3Q34407923-FCCE1D6C-816A-4E13-8A92-3EDC4D7AC370Q34539515-D7768680-6990-440A-AB54-0D5F486BCC3AQ34562770-E2B6F6AD-53E3-4A24-B572-F1CAB995F1B3Q34697234-5171D6B9-4C0B-45D4-801D-2923CBA1ABEAQ34744094-2D2F8429-4933-4755-ACF7-E9F5A4635D6BQ34974251-775A6DE7-BA8F-4066-9562-4D83039185E9Q35037456-1965ABBF-DF0A-4324-B525-C876AED21CCFQ35038034-912E3514-92F0-4164-B85D-F0B4B7FB5482Q35038039-C3D4C163-AB44-44C8-96B1-050A25F33E06Q35038056-4532E561-CE2A-4CD8-813D-F4C1EDC21BE4Q35736698-9F439257-A77A-45CB-A2D2-F0E2F5358135Q35772582-06E3A2A3-A5D8-4687-8457-3807C875E7CEQ35779527-4B6AFCDC-249F-4C38-B311-3DC448AC5EE1Q35784527-2408C688-910E-4144-8D8C-D38C446DFDFDQ35834289-3FC2FE12-2C71-4C7A-99A5-995AA2F15364Q35876017-8D28DEC0-786A-4617-A108-D3B8E78DFB87Q35889605-F54BBB93-77E6-4020-B270-4FC6B27883A7Q35889610-8799A75F-7B87-4A17-98B3-CB0DF9649851Q35889619-CF037F15-B83A-4418-A517-6C0B0B2BF0EFQ36001208-C6603C76-5F8A-4E38-A5D1-810E2CFE96E0Q36180606-2C8711B6-3628-4CEF-84F2-1BD532A13215Q36186955-7B8AF270-AEA6-4EC2-95A6-4C965F93AE69Q36255125-9655EDBD-93D5-40D1-A1E6-8D097C3A67C7Q36265259-648FC241-8909-4232-86E4-80604E48C4B5Q36273420-8C2FF73F-B254-47DB-9BF6-C5DFA1191220Q36288606-E370FC4C-A45F-4B15-81B5-FB94A3CE5840Q36294685-E5654021-4981-4EF8-9CA8-9A0976DC22EE
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Pharmacogenetics goes genomic.
@ast
Pharmacogenetics goes genomic.
@en
type
label
Pharmacogenetics goes genomic.
@ast
Pharmacogenetics goes genomic.
@en
prefLabel
Pharmacogenetics goes genomic.
@ast
Pharmacogenetics goes genomic.
@en
P2093
P2860
P356
P1476
Pharmacogenetics goes genomic.
@en
P2093
David B Goldstein
Sanjay M Sisodiya
Sarah K Tate
P2860
P2888
P304
P356
10.1038/NRG1229
P577
2003-12-01T00:00:00Z
P5875
P6179
1047189229